Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
Wednesday, April 29, 2020 1 min read
Key Takeaway: Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
Full Press Release Details
Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology.